About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Why weight-loss drugs are the top target of Medicare price negotiations

By: Equities.com
Why weight-loss drugs are the top target of Medicare price negotiations

The federal government is looking to reduce the cost of certain medications. There is currently a major “price negotiation” underway. A few thoughts:

Everyone is talking about or using weight loss products. So, the government pounces. A batch of 17 drugs are on a list of medications in a second round of price negotiations that would go into effect in 2027.

It should be no surprise that Ozempic, Wegovy and Rybelsus are at the top of the list. These stars cost Medicare more than $7.5 billion a year according to various sources. It should also be no surprise that Danish pharmaceutical company Novo Nordisk NVO , which makes those three drugs, is opposed to the price negotiation process.

The other 14 drugs at the center of the target are also significant:

  1. Trelegy Ellipta, GlaxoSmithKline GSK : Used for asthma and COPD.
  2. Xtandi, Pfizer PFE and Astellas Pharma ALPMY : Used to treat prostate cancer.
  3. Pomalyst, Bristol Myers Squibb : A chemotherapy drug used to treat Kaposi sarcoma and multiple myeloma.
  4. Ibrance, Pfizer: A breast cancer drug.
  5. Ofev, Boehringer Ingelheim Pharmaceuticals: For idiopathic pulmonary fibrosis.
  6. Linzess, AbbVie ABBV and Ironwood Pharmaceuticals : For treatment of chronic constipation.
  7. Calquence, AstraZeneca AZN : A cancer drug.
  8. Austedo and Austedo XR, Teva TEVA : For treatment of Huntington’s disease.
  9. Breo Ellipta, GlaxoSmithKline and Theravance TBPH : Used for COPD.
  10. Tradjenta, Boehringer Ingelheim: Used to treat diabetes.
  11. Xifaxan, Bausch Health Companies BHC : For diarrhea and irritable bowel syndrome.
  12. Vraylar, AbbVie and Gedeon Richter Plc: An antipsychotic drug.
  13. Janumet and Janumet XR, Merck & Co. MRK : Used to treat diabetes.
  14. Otezla, Amgen AMGN : For psoriatic arthritis.

Note that they ticked off the very popular medications and a bunch of others to appear even handed. The government’s purpose is obvious: go after rich pharmaceutical companies and expensive drugs to gain maximum political advantage. For example, for people not covered by insurance, a month’s supply of Vraylar costs roughly $2,000.

There are always rumors that in such and such a country, such and such a medication is cheap and health care is much more efficient. These rumors are hard – more likely impossible — to verify, but they carry weight with elected officials.

The size and complexity of health care in the U.S. make its health care practice – not really a system – difficult to characterize. In the COVID years, the government provided a great deal of the funding for vaccinations. The pharmaceutical companies gained a huge financial benefit.

Also, the U.S. is where most of the major medical advances based on research and development take place. In fact, the taxpayers who are puncturing themselves with weight-loss miracle drugs actually played some role in their creation.

Cutting outrageous prices and profits may reduce future R&D. For investors, this should be a major consideration. While the government got behind the search for a near-perfect COVID vaccine, diseases that affect smaller numbers of people and therefore build up less political clout are unlikely to gain massive taxpayer funding.

The giant and emerging stars of the industry will have to keep up their R&D efforts to discover effective medications.

The government loves to find high profits it can tax. Years ago, it was after oil companies. Exxon was a big target. Hillary Clinton once said, “There is something seriously wrong with our economy when Exxon’s record $11 billion in quarterly profits are seen as a disappointment by Wall Street.” She was later criticized for accepting donations from executives and employees of oil companies during the 2008 campaign.

The pharmaceutical companies have amassed huge piles of cash over the last five years, especially from COVID-19 and all the tax money poured into the industry. Now, the medicine makers are squarely in the sights of politicians who do not like high profits.

More from Michael McTague: Pharma industry ripe for M&A in 2025

More News

View More
Rocket Lab: A Space Giant Hitting New Highs—Time to Chase?
Via MarketBeat
Tickers RKLB
Lowe’s vs. Home Depot: Which Benefits More From Lower Rates?
Via MarketBeat
Topics Economy
Tickers AMD HD LOW
These 5 Beaten-Down Tech Stocks Could Catch Fire Next
Via MarketBeat
Topics Artificial Intelligence
Tickers ASTS ETSY OPEN SOUN TEM
Falcon Flex Drives Growth as CrowdStrike Bets on AI Security
Via MarketBeat
Topics Artificial Intelligence
Tickers CRWD
Amphenol: The Unseen Giant Behind Every Major Tech Trend
Via MarketBeat
Topics Artificial Intelligence
Tickers APH COMM
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.